Breast cancer in young women and prognosis: How important are proliferation markers?
- 1 October 2017
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 84, 278-289
- https://doi.org/10.1016/j.ejca.2017.07.044
Abstract
No abstract availableThis publication has 51 references indexed in Scilit:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression ProfilingClinical Cancer Research, 2012
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI Journal of the National Cancer Institute, 2011
- Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancerAnnals of Oncology, 2010
- Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast CancerClinical Cancer Research, 2009
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI Journal of the National Cancer Institute, 2009
- Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage DiseaseJournal of the American College of Surgeons, 2009
- The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotypeHuman Pathology, 2008
- Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patientsPathology International, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001